Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) had its price objective decreased by equities researchers at Wedbush from $10.00 to $8.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Wedbush's price objective suggests a potential downside of 5.66% from the company's previous close.
Other equities research analysts also recently issued reports about the company. Citigroup assumed coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They issued a "buy" rating and a $16.00 price target for the company. HC Wainwright began coverage on shares of Voyager Therapeutics in a research report on Tuesday, March 19th. They issued a "buy" rating and a $30.00 target price on the stock. Guggenheim initiated coverage on shares of Voyager Therapeutics in a research report on Tuesday, March 26th. They issued a "buy" rating and a $22.00 price target for the company. Finally, StockNews.com cut shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $17.67.
Get Our Latest Report on Voyager Therapeutics
Voyager Therapeutics Stock Performance
Shares of NASDAQ:VYGR remained flat at $8.48 during trading hours on Tuesday. 567,997 shares of the stock traded hands, compared to its average volume of 843,985. The company's 50 day simple moving average is $8.81 and its two-hundred day simple moving average is $8.07. The stock has a market cap of $461.21 million, a P/E ratio of 2.72 and a beta of 0.98. Voyager Therapeutics has a one year low of $6.06 and a one year high of $14.34.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $1.84. The firm had revenue of $90.06 million during the quarter, compared to analysts' expectations of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. Analysts expect that Voyager Therapeutics will post -1.64 EPS for the current fiscal year.
Institutional Investors Weigh In On Voyager Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. increased its stake in shares of Voyager Therapeutics by 49.6% in the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company's stock worth $37,000 after acquiring an additional 1,300 shares during the last quarter. SummerHaven Investment Management LLC increased its position in Voyager Therapeutics by 1.9% in the 4th quarter. SummerHaven Investment Management LLC now owns 74,146 shares of the company's stock worth $626,000 after purchasing an additional 1,367 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Voyager Therapeutics by 0.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 192,869 shares of the company's stock worth $1,495,000 after purchasing an additional 1,455 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Voyager Therapeutics by 2.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company's stock valued at $925,000 after buying an additional 2,030 shares during the last quarter. Finally, Ritholtz Wealth Management grew its stake in shares of Voyager Therapeutics by 11.8% in the 4th quarter. Ritholtz Wealth Management now owns 19,759 shares of the company's stock valued at $167,000 after buying an additional 2,089 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company's stock.
About Voyager Therapeutics
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Further Reading
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
